New Data on Dupilumab Reinforces Its Impact on Chronic Respiratory Diseases

©Visual Generation/AdobeStock

Regeneron Pharmaceuticals, in partnership with Sanofi, will unveil new clinical findings for dupilumab (Dupixent®) at the upcoming American Thoracic Society (ATS) International Conference 2025, being held May 18-21 in San Francisco, California.^1,2

The data, including late-breaking posters and an oral presentation, highlights the benefits of dupilumab in treating chronic respiratory diseases driven by type 2 inflammation, such as chronic obstructive pulmonary disease (COPD) and asthma.^1,2

The findings from pivotal phase 3 studies, such as BOREAS and NOTUS, underscore the efficacy of dupilumab in improving lung function and reducing exacerbations in people with COPD, with or without emphysema. Notably, the studies revealed that the use of dupilumab significantly reduced exacerbations and enhanced lung function across a broad patient population. Moreover, the drug’s effects were sustained through 52 weeks, highlighting its long-term potential in improving patient outcomes. These findings were reinforced by a win-ratio post-hoc analysis, which further demonstrated the drug's potential to reduce the risk of severe events such as hospitalization, lung function decline, and death.^1,2

In asthma, dupilumab showed promising results in both adult and pediatric populations. Data from the phase 4 VESTIGE study revealed a reduction in mucus burden—a key driver of asthma symptoms—as measured by mucous plug scores and volume, and regardless of baseline fractional exhaled nitric oxide levels, as early as week 4. The VOYAGE trial also showed that dupilumab significantly reduced exacerbations in children aged 6 to 11 years, regardless of disease duration. Both studies reinforced the drug’s broad potential across diverse asthma phenotypes.²

Additionally, dupilumab demonstrated positive results in the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma, with improvements in lung function, exacerbations, and health-related quality of life. This phase 2 data will be shared in an oral presentation during the conference.^1,2

“Across the Dupixent clinical program and our immunology pipeline, these results hold promise to make a positive impact on key clinical endpoints, including lung function, across chronic obstructive pulmonary disease, asthma and other diseases,” Alyssa Johnsen, MD, PhD, Global Therapeutic Area Head, Immunology and Oncology Development, Sanofi, said in a press release.²

Dupilumab, which targets the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways, has been shown to reduce type 2 inflammation, a central driver in many chronic respiratory and allergic conditions. The drug has received regulatory approvals in over 60 countries for various indications, including moderate-to-severe asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, and COPD. The safety profile of dupilumab observed in these studies was consistent with previous trials, with common adverse events including viral infections, headache, and injection site reactions.^1,2

References:

• Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases. News release. Regeneron. May 1, 2025. Accessed May 1, 2025. https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-data-presented-ats-reinforce-impact
• Media Update: ATS: Sanofi showcases leadership and breadth of scientific innovation in chronic inflammatory respiratory conditions. News release. Sanofi. May 1, 2025. Accessed May 1, 2025. https://www.sanofi.com/en/media-room/press-releases/2025/2025-05-01-12-58-20-3072425